Successful completion of USFDA inspection at Alembic Pharmaceuticals Limited’ Oral Solid Formulation Facility (F-I) at Panelav

Bengaluru: Alembic Pharmaceuticals Limited announced that it has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Oral Solid Formulation Facility (F-I) located at Panelav.

This was a scheduled GMP inspection and was successfully completed without any Form 483 observation. The inspection was conducted from 17th July, 2024 to 26th July, 2024.

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic’s state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic’s brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.